HALO
Deal drama, but make it biotech
Halozyme Therapeutics spent earlier this month flirting with a pretty expensive date: buying German drug developer Evotec for about €2 billion. Now the company says it’s done waiting around and has withdrawn the offer after Evotec’s management refused to engage.
Why this matters
On paper, the combo had a neat logic. Halozyme brings drug-delivery tech; Evotec brings drug discovery and development services. Together, they could’ve looked like one of those “synergy” slides that bankers love to slap on a PowerPoint and call it destiny.
But the market rarely cares about slide decks. It cares about execution, and right now Evotec is in the middle of its own cleanup job. Revenues have been under pressure, the stock has already been knocked around hard this year, and management says it wants to stay independent while it runs its “Priority Reset” restructuring.
What investors should watch next
- Halozyme no longer has to stretch for a pricey cross-border acquisition
- Evotec keeps its independence, at least for now, but still has to prove the turnaround is real
- The whole episode is a reminder that strategic logic doesn’t always beat shareholder skepticism
Big picture: Halozyme didn’t just lose a target — it lost a potential growth shortcut. Now the company has to keep convincing investors that its own business can carry the load without a €2 billion assist.